Last reviewed · How we verify

NCT04303390

24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis

Completed Phase 4 Last updated 11 April 2023
What this trial tests

Phase 4 trial testing Cefuroxime in Surgical Site Infection in 568 participants. Completed in 31 May 2022.

Timeline
6 February 2018
Primary endpoint
31 May 2022
31 May 2022

Quick facts

Lead sponsorSaud Al Babtain Cardiac Center
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment568
Start date6 February 2018
Primary completion31 May 2022
Estimated completion31 May 2022
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

Saud Al Babtain Cardiac Center

Who can join

18 and older, any sex, with Surgical Site Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized control trial studying the effect of prophylactic antibiotics to reduce surgical site infections following cardiac surgery in adults using 1st generation cephalosporin (Cefazolin) or 2nd generation cephalosporin (Cefuroxime).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cefuroxime

Trials testing the same drug.

Other recruiting trials for Surgical Site Infection

Currently open trials in the same condition.

Other Saud Al Babtain Cardiac Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04303390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing